Neuroprotective properties of dehydroepiandrosterone-sulfate and its relationship to interleukin 6 after aneurysmal subarachnoid hemorrhage: a prospective cohort study

Table 3 DHEAS levels during the inpatient stay according to functional outcome at discharge (dichotomized modified Rankin Scale score)

	Minimum	Maximum	Mean	SD	95 % CI	Number
DHEAS day 0
Favorable	<150	5260	1431	1077	1081, 1782	38
Unfavorable	<150	2370	955	730	712, 1199	37
DHEAS day 1
Favorable	<150	4460	1132	989	802, 1462	37
Unfavorable	<150	2740	785	646	566, 1004	36
DHEAS day 4
Favorable	<150	2840	710	662	486, 934	36
Unfavorable	<150	1700	223	453	215, 542	32
DHEAS day 7
Favorable	<150	3780	781	796	507, 1054	35
Unfavorable	<150	1110	282	343	156, 407	31
DHEAS day 10
Favorable	<150	5770	961	1202	542, 1380	34
Unfavorable	<150	937	247	245	152, 342	28
DHEAS day 14
Favorable	<150	2560	634	602	405, 863	29
Unfavorable	<150	1520	371	430	189, 553	24

Dehydroepiandrosterone-sulfate (DHEAS) levels (ng/ml) during the acute stage of disease according to dichotomized (Favorable vs Unfavorable modified Rankin Scale score) outcome at discharge. Number number of cases analyzed

ISSN: 1364-8535